Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma

Industry News

Idera Pharmaceuticals, a biopharmaceutical company based in Cambridge, MA announced that the FDA has granted orphan drug designation for IMO-8400 for the treatment of diffuse large B-cell lymphoma (DLBCL).  IMO-8400 is an oligonucleotide antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9.  Preclinical studies have shown that in B‐cell lymphomas with the MYD88 L265P oncogenic mutation, including DLBCL, manifest higher TLR signaling and IMO-8400 inhibits over-activated TLR signaling.  Idera is currently sponsoring a phase I/II clinical trial evaluating its safety and efficacy in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation.


Original Article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.